- Notification that Annual Report will be submitted late (NT 10-K)
2009年3月31日 - 7:06PM
Edgar (US Regulatory)
U.S.
SECURITIES AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
12b-25
NOTIFICATION
OF LATE FILING
Commission File Number
000-19195
(Check
One):
[X
] Form 10-K and Form 10-KSB [ ] Form
11-K
[ ]
Form 20-F [ ] Form 10-Q and Form
10-QSB [ ] Form N-SAR
For
Period Ended:
December 31,
2008
[ ] Transition
Report on Form 10-K and Form 10-KSB
[ ] Transition
Report on Form 20-F
[ ] Transition
Report on Form 11-K
[ ] Transition
Report on Form 10-Q and Form 10-QSB
[ ] Transition
Report on Form N-SAR
For
the Transition Period Ended:
Read
Attached Instruction Sheet Before Preparing Form. Please Print or
Type.
Nothing
in this form shall be construed to imply that the Commission has verified any
information contained herein.
If
the notification relates to a portion of the filing checked above, identify the
item(s) to which the notification relates:
|
PART
I
|
REGISTRANT
INFORMATION
|
Full
Name of Registrant
|
American
Medical Technologies, Inc.
|
Former
Name if Applicable
|
|
|
|
Address
of Principal Executive
|
|
Offices
(Street and
Number)
|
5655
Bear Lane
|
|
|
City,
State and Zip Code
|
Corpus
Christi, Texas 78405
|
|
PART
II
|
RULE
12b-25(b) AND
(c)
|
If
the subject report could not be filed without unreasonable effort or expense and
the registrant seeks relief pursuant to Rule 12b-25 (b), the following should be
completed. (Check appropriate box)
/X/
|
(a)
|
The
reasons described in reasonable detail in Part III of this form could not
be eliminated without unreasonable effort or expense;
|
|
|
|
/X/
|
(b)
|
The
subject annual report, semi-annual report, transition report on Form 10-K,
10-KSB, 20-F, 11-K or Form N-SAR, or portion thereof will be filed on or
before the 15th calendar day following the prescribed due date; or the
subject quarterly report or transition report on Form 10-Q, 10-QSB, or
portion thereof will be filed on or before the fifth calendar day
following the prescribed due date; and
|
|
|
|
/ /
|
(c)
|
The
accountant's statement or other exhibit required by Rule 12b-25(c) has
been attached if applicable.
|
State
below in reasonable detail the reasons why Forms 10-K, 10-KSB, 11-K. 20-F, 10-Q,
10-QSB, N-SAR, or the transition report or portion thereof could not be filed
within the prescribed time period.
(Attach extra sheets if
needed.)
The
registrant has experienced delays in completing its financial statements for the
year ended December 31, 2008, as its auditor has not had sufficient time to
audit its financial statements for the year ended December 31, 2008. As a
result, the registrant is delayed in filing its Form 10-K for the year ended
December 31, 2008.
|
PART
IV
|
OTHER
INFORMATION
|
(1)
Name and telephone number of person to contact in regard to this
notification
David M. Loev
|
(713)
|
524-4110
|
(Name)
|
(Area
Code)
|
(Telephone
Number)
|
(2)
Have all other periodic reports required under Section 13 or 15(d) of the
Securities Exchange Act of 1934 or Section 30 of the Investment Company
Act of 1940 during the preceding 12 months or for such shorter period that
the registrant was required to file such report(s) been
filed? If the answer is no, identify
report(s).
|
[X]
Yes [ ] No
(3)
Is it anticipated that any significant change in results of operations
from the corresponding period for the last fiscal year will be reflected
by the earnings statements to be included in the subject report or portion
thereof?
|
[ ]
Yes [X] No
If
so, attach an explanation of the anticipated change, both narratively and
quantitatively, and, if appropriate, state the reasons why a reasonable estimate
of the results cannot be made.
AMERICAN MEDICAL
TECHNOLOGIES, INC.
(Name
of Registrant as specified in charter)
Has
caused this notification to be signed on its behalf by the undersigned hereunto
duly authorized.
Date:
March 30, 2009
|
By
:
/s/
Jeffrey Goodman
|
|
Jeffrey
Goodman, Chief Executive
Officer
|
INSTRUCTION: The
form may be signed by an executive officer of the registrant or by any other
duly authorized representative. The name and title of the person
signing the form shall be typed or printed beneath the signature. If
the statement is signed on behalf of the registrant by an authorized
representative (other than an executive officer), evidence of the
representative's authority to sign on behalf of the registrant shall be filed
with the form.
ATTENTION
Intentional
misstatements or omissions of fact constitute Federal criminal violations (see
18 U.S.C. 1001).
GENERAL
INSTRUCTIONS
1.
|
This
form is required by Rule 12b-25 of the General Rules and Regulations under
the Securities Exchange Act of 1934.
|
|
|
2.
|
One
signed original and four conformed copies of this form and amendments
thereto must be completed and filed with the Securities and Exchange
Commission, Washington, D.C. 20549, in accordance with Rule 0-3 of the
General Rules and Regulations under the Act. The information
contained in or filed with the Form will be made a matter of the public
record in the Commission files.
|
|
|
3.
|
A
manually signed copy of the form and amendments thereto shall be filed
with each national securities exchange on which any class of securities of
the registrant is registered.
|
|
|
4.
|
Amendments
to the notification must also be filed on Form 12b-25 but need not restate
information that has been correctly furnished. The form shall
be clearly identified as an amended
notification.
|
American Medical Technol... (CE) (USOTC:ADLI)
過去 株価チャート
から 11 2024 まで 12 2024
American Medical Technol... (CE) (USOTC:ADLI)
過去 株価チャート
から 12 2023 まで 12 2024